Insulin shortage — AU supply status & alternatives

Insulin

—

🇦🇺 AUST R 328580 · Novo Nordisk Pharmaceuticals Pty Ltd

In shortage · Australia

In declared shortage · 🇦🇺 Australia & also short in🇨🇦 CA🌐 MY

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

🇦🇺 AUAEMPA$13.60DPMQ A$85.24details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)

Therapeutic category	Auto-created by National Pharmaceutical Regulatory Agency — Safety Alerts scraper

Controlled substance	No

Marketing-authorisation holders	Novo Nordisk Pharmaceuticals Pty Ltd, Eli Lilly Australia Pty Ltd, WOCKHARDT UK LIMITED, Eli Lilly and Company +2 more

Registrations on file	24

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$13.60

AEMP

Dispensed (DPMQ)

A$85.24

incl. fees

Pack

insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 10 mL vial

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

1 API manufacturer

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Very high concentration risk

Mj Biopharm PVT LTD

Country of manufacture not yet mapped · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇦🇺

Australia

TGA · 3h ago

High

🇨🇦

Canada

HC · 9h ago

High

🌐

NPRA · just now

Medium

Recalls official enforcement reports

🇺🇸

Insulin

Abbott's Compounding Pharmacy, Inc. · Jan 2016

Class IIdetails ↗

🇺🇸

Insulin

Franck's Lab Inc., d.b.a. Franck's Compounding Lab · May 2012

Class IIdetails ↗

Verified timeline regulator events

🇦🇺 31 Dec 2026

high reported

🇦🇺 30 Sept 2026

high reported

🇦🇺 31 July 2026

high reported

🇨🇦 16 Apr 2026

high reported

🇦🇺 31 Mar 2026

high reported

🌐 1 Jan 2020

medium reported

Sources official regulators

🌐

NPRA

verified just now

verify ↗

🇦🇺

TGA

verified 3h ago

verify ↗

🇨🇦

verified 9h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders24 registrations · 6 MA holders

Product	Strength	Form	Market	MA holder	Status
XULTOPHY insulin degludec	100 units	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Novomix	3mL	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
BASAGLAR insulin glargine	100 IU	injsol	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
BASAGLAR KwikPen insulin glargine	100 IU	injsol	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
FIASP FLEXTOUCH insulin aspart	100 units	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Biphasic Isophane Insulin Injection Bp	—	injection	🇬🇧 GB	WOCKHARDT UK LIMITED	Active
Insulin Lispro	100[iU]/mL	injection	🇺🇸 US	Eli Lilly and Company	Active
Lispro Protamine and Insulin Lispro	100[iU]/mL	injection	🇺🇸 US	Eli Lilly and Company	Active
Insulin Diluting Medium for NovoLog	1mL/mL	injection	🇺🇸 US	Novo Nordisk	Active
HUMULIN NPH human insulin	100IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMULIN R insulin	100IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
Humulin	30%	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMULIN NPH biosynthetic human isophane insulin	100IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMULIN R biosynthetic human neutral insulin	100IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active
HUMALOG insulin lispro	100 IU	—	🇦🇺 AU	Eli Lilly Australia Pty Ltd	Active

+9 more registrations on file

Mederti Drug Report

Generated 1 July 2026 · Australia market · 3 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.